Moreover, recent studies have shown that niclosamide (an antihelminthic drug) and its derivative (HJC0152) enhance the efficacy of immunotherapy in NSCLC by blocking the binding of pSTAT3 to the PD-L1 promoter, thus downregulating the expression of PD-L1 [28,35]. Here, CD274 is linked to non-small cell lung carcinoma.